GT Biopharma (NASDAQ: GTBP) stock fell by 27% in the past month. This clinical stage immuno-oncology company has three product candidates in its clinical pipeline, which are all in the early phases of study. So, is this stock worth buying now?
GT Biopharma focused on innovative therapies based on its proprietary NK cell engager (TriKE) technology. TriKE therapeutic agents are targeted immunotherapeutic agents that have been modified from a bispecific antibody platform.
GTB-3550 is its first TriKE product candidate for the treatment of acute myeloid leukemia, which is in Phase 1 study. The company said that the Phase 1 safety part of the GTB-3550 is expected to conclude in late August 2021 with data publication currently scheduled for end of September 2021.
GT Biopharma’s TriKE platform is also being studied in other cancers, including breast, lung, gastric, colorectal, and ovarian indications, but these are in the early phases of study.
Some analysts have raised their expectations for GTB-3550. They believed that with the dose-escalation portion of the trial expected to complete towards the end of August 2021, they are raising its probability of success for GTB-3550. In addition, GTBP stock has already had a 55% rise so far this year. With all of this in mind, GTBP stock is still worth watching closely.
Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.